Abstract
Introduction: Rubinstein-Taybi syndrome (RTS) is a rare genetic condition with a distinctive set of physical features. This case series reports a single institutional experience of RTS cases, highlighting the role of neurosurgery in the comprehensive management of RTS patients. Methods: A retrospective review of patients with genetically confirmed RTS presenting between 2010 and 2023 at Children’s Hospital of Pittsburgh was performed. Patient demographics, genetic profile, clinical symptoms, radiographic characteristics, and neurosurgical management were recorded for all patients. Results: Twenty-one patients (13 females, 8 males) aged 0 to 22 years presented for formal genetic counseling and diagnosis. Twenty patients (95%) had CREBBP pathogenic variants (RTS type 1), and 1 patient (5%) had EP300 pathogenic variants (RTS type 2). Ten patients (48%) had a low-lying conus medullaris, and 3 patients (30%) underwent subsequent spinal cord detethering. Four patients (19%) had a Chiari malformation, and three (75%) underwent Chiari decompression surgeries. One patient (5%) had Chiari-associated syringomyelia. Conclusions: RTS patients have an increased rate of tethered cord syndrome requiring detethering. The incidence of symptomatic Chiari I malformation requiring decompression has not been previously reported. The RTS series presented here demonstrates a high incidence of symptomatic Chiari I malformation in addition to tethered cord syndrome.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Stevens
CA
. Rubinstein-taybi syndrome
. In: Adam
MP
, Mirzaa
GM
, Pagon
RA
, Wallace
SE
, Bean
LJH
, Gripp
KW
, et al, editors. GeneReviews((R))
. Seattle (WA)
; 1993
.2.
Milani
D
, Manzoni
FM
, Pezzani
L
, Ajmone
P
, Gervasini
C
, Menni
F
, et al. Rubinstein-Taybi syndrome: clinical features, genetic basis, diagnosis, and management
. Ital J Pediatr
. 2015
;41
:4
. 3.
Coupry
I
, Roudaut
C
, Stef
M
, Delrue
MA
, Marche
M
, Burgelin
I
, et al. Molecular analysis of the CBP gene in 60 patients with Rubinstein-Taybi syndrome
. J Med Genet
. 2002
;39
(6
):415
–21
. 4.
Imaizumi
K
, Kuroki
Y
. Rubinstein-Taybi syndrome with de novo reciprocal translocation t(2;16)(p13.3;p13.3)
. Am J Med Genet
. 1991
;38
(4
):636
–9
. 5.
Negri
G
, Milani
D
, Colapietro
P
, Forzano
F
, Della Monica
M
, Rusconi
D
, et al. Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene
. Clin Genet
. 2015
;87
(2
):148
–54
. 6.
Fergelot
P
, Van Belzen
M
, Van Gils
J
, Afenjar
A
, Armour
CM
, Arveiler
B
, et al. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations
. Am J Med Genet A
. 2016
;170
(12
):3069
–82
. 7.
Lee
JS
, Byun
CK
, Kim
H
, Lim
BC
, Hwang
H
, Choi
JE
, et al. Clinical and mutational spectrum in Korean patients with Rubinstein-Taybi syndrome: the spectrum of brain MRI abnormalities
. Brain Dev
. 2015
;37
(4
):402
–8
. 8.
Tanaka
T
, Ling
BC
, Rubinstein
JH
, Crone
KR
. Rubinstein-Taybi syndrome in children with tethered spinal cord
. J Neurosurg
. 2006
;105
(4 Suppl l
):261
–4
. 9.
Horn
S
, Moses
M
, Vasquez-Montes
D
, Hockley
A
, Poorman
G
, Bortz
C
, et al. Tethered cord syndrome in the United States cluster analysis of presenting anomalies and associated
. Bull Hosp Jt Dis
. 2020
;78
(3
):157
–62
.10.
Boot
MV
, van Belzen
MJ
, Overbeek
LI
, Hijmering
N
, Mendeville
M
, Waisfisz
Q
, et al. Benign and malignant tumors in Rubinstein-Taybi syndrome
. Am J Med Genet A
. 2018
;176
(3
):597
–608
. 11.
Schorry
EK
, Keddache
M
, Lanphear
N
, Rubinstein
JH
, Srodulski
S
, Fletcher
D
, et al. Genotype-phenotype correlations in Rubinstein-Taybi syndrome
. Am J Med Genet A
. 2008
;146A
(19
):2512
–9
. 12.
Ishizaka
S
, Sou
G
, Morofuji
Y
, Hayashi
K
, Kitagawa
N
, Tateishi
Y
, et al. [Dissecting aneurysm of the anterior cerebral artery with Rubinstein-Taybi syndrome: a case report]
. Brain Nerve
. 2010
;62
(10
):1083
–8
.13.
Verstegen
MJ
, van den Munckhof
P
, Troost
D
, Bouma
GJ
. Multiple meningiomas in a patient with Rubinstein-Taybi syndrome. Case report
. J Neurosurg
. 2005
;102
(1
):167
–8
. 14.
Siraganian
PA
, Rubinstein
JH
, Miller
RW
. Keloids and neoplasms in the Rubinstein-Taybi syndrome
. Med Pediatr Oncol
. 1989
;17
(5–6
):485
–91
. 15.
Miller
RW
, Rubinstein
JH
. Tumors in rubinstein-taybi syndrome
. Am J Med Genet
. 1995
;56
(1
):112
–5
. 16.
Park
CH
, Park
KH
, Choi
BY
. Management of anesthesia for rubinstein-taybi syndrome
. Korean J Anesthesiol
. 2012
;63
(6
):571
–2
. 17.
Critchley
LA
, Gin
T
, Stuart
JC
. Anaesthesia in an infant with Rubinstein-Taybi syndrome
. Anaesthesia
. 1995
;50
(1
):37
–8
. 18.
Altintas
F
, Cakmakkaya
S
. Anesthetic management of a child with Rubinstein-Taybi syndrome
. Paediatr Anaesth
. 2004
;14
(7
):610
–1
. 19.
Desurkar
V
, Junghare
S
. Congenital heart diseases and anaesthesia
. Indian J Anaesth
. 2017
;61
(9
):744
–52
. 20.
McLendon
RE
, Oakes
JW
, Heinz
RE
, Yeates
AE
, Burger
PC
. Adipose tissue in the filum terminale: a computed tomographic finding that may indicate tethering of the spinal cord
. Neurosurgery
. 1988
;22
(5
):873
–6
. 21.
Giussani
C
, Selicorni
A
, Fossati
C
, Ingelmo
P
, Canonico
F
, Landi
A
, et al. The association of neural axis and craniovertebral junction anomalies with scoliosis in Rubinstein-Taybi syndrome
. Childs Nerv Syst
. 2012
;28
(12
):2163
–8
. 22.
Hadzsiev
K
, Gyorsok
Z
, Till
A
, Czako
M
, Bartsch
O
. Rubinstein-Taybi syndrome 2 with cerebellar abnormality and neural tube defect
. Clin Dysmorphol
. 2019
;28
(3
):137
–41
. 23.
Marzuillo
P
, Grandone
A
, Coppola
R
, Cozzolino
D
, Festa
A
, Messa
F
, et al. Novel cAMP binding protein-BP (CREBBP) mutation in a girl with Rubinstein-Taybi syndrome, GH deficiency, Arnold Chiari malformation and pituitary hypoplasia
. BMC Med Genet
. 2013
;14
(1
):28
. 24.
Kim
SH
, Lim
BC
, Chae
JH
, Kim
KJ
, Hwang
YS
. A case of Rubinstein-Taybi Syndrome with a CREB-binding protein gene mutation
. Korean J Pediatr
. 2010
;53
(6
):718
–21
. 25.
Parsley
L
, Bellus
G
, Handler
M
, Tsai
AC
. Identical twin sisters with Rubinstein-Taybi syndrome associated with Chiari malformations and syrinx
. Am J Med Genet A
. 2011
;155A
(11
):2766
–70
. 26.
Wojcik
C
, Volz
K
, Ranola
M
, Kitch
K
, Karim
T
, O'Neil
J
, et al. Rubinstein-Taybi syndrome associated with Chiari type I malformation caused by a large 16p13.3 microdeletion: a contiguous gene syndrome
. Am J Med Genet A
. 2010
;152A
(2
):479
–83
. 27.
Aitken
LA
, Lindan
CE
, Sidney
S
, Gupta
N
, Barkovich
AJ
, Sorel
M
, et al. Chiari type I malformation in a pediatric population
. Pediatr Neurol
. 2009
;40
(6
):449
–54
. 28.
Sadler
B
, Kuensting
T
, Strahle
J
, Park
TS
, Smyth
M
, Limbrick
DD
, et al. Prevalence and impact of underlying diagnosis and comorbidities on Chiari 1 malformation
. Pediatr Neurol
. 2020
;106
:32
–7
. 29.
Leon
TJ
, Kuhn
EN
, Arynchyna
AA
, Smith
BP
, Tubbs
RS
, Johnston
JM
, et al. Patients with “benign” Chiari I malformations require surgical decompression at a low rate
. J Neurosurg Pediatr
. 2019
;23
(4
):498
–506
. 30.
Wiley
S
, Swayne
S
, Rubinstein
JH
, Lanphear
NE
, Stevens
CA
. Rubinstein-Taybi syndrome medical guidelines
. Am J Med Genet A
. 2003
;119A
(2
):101
–10
. 31.
Bartsch
O
, Wagner
A
, Hinkel
GK
, Krebs
P
, Stumm
M
, Schmalenberger
B
, et al. FISH studies in 45 patients with Rubinstein-Taybi syndrome: deletions associated with polysplenia, hypoplastic left heart and death in infancy
. Eur J Hum Genet
. 1999
;7
(7
):748
–56
. 32.
Bourdeaut
F
, Miquel
C
, Richer
W
, Grill
J
, Zerah
M
, Grison
C
, et al. Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma
. Pediatr Blood Cancer
. 2014
;61
(2
):383
–6
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
